Supplementary file

Characteristics and risk factors for SARS-CoV-2 among children in Italy: a cross-sectional study in 20 pediatric centers

This supplementary material is hosted by Eurosurveillance as supporting information alongside the article Characteristics and risk factors for SARS-CoV-2 among children in Italy tested in the early phase of the pandemic: a cross-sectional study, on behalf of the authors, who remain responsible for the accuracy and appropriateness of the content. The same standards for ethics, copyright, attributions and permissions as for the article apply. Supplements are not edited by Eurosurveillance and the journal is not responsible for the maintenance of any links or email addresses provided therein.

Table of content

Supplementary Table 1. Criteria for disease severity	2
Supplementary Table 2. Definition of tachypnea and tachycardia	
Supplementary Table 3. Treatments and outcomes of children SARS-CoV-2 positive	4
Supplementary Table 4. Characteristics of children tested for SARS-COv-2 because of contact with a positive case or within hospitals screening	
Supplementary Table 6. Disease severity by age group in positive children with symptoms suggestive of COVID-19	8
Supplementary Figure 1. Geographical distribution of total cases (N=2494) and positive cases (N=190)	9
Supplementary Figure 2. Percentage of SARS-CoV-2 positive cases across centers	.0

Supplementary Table 1. Criteria for disease severity

Asymptomatic: all the following must be present

- 1. No signs or symptoms
- 2. AND Negative Chest X-Ray
- 3. AND absence of criteria for other cases

Mild: any of the following (AND absence of criteria for more severe cases)

- 1. Symptoms of upper respiratory tract infection
- 2. AND absence of pneumonia at chest X-ray

Moderate: all the following (AND absence of criteria for more severe cases)

- 1. Cough or other symptom/sign AND pneumonia at chest X-ray
- 2. CT with lung lesions

Severe: any of the following (AND absence of criteria as for critical case)

- 1. Oxygen saturation <92% OR
- 2. Difficult breathing or other signs of severe respiratory distress (apnea, gasping, head nodding) or any other danger sign such as convulsion, restlessness, lethargy, severe dehydration, reduced reactivity, hypotonia
- 3. OR need for any respiratory support

Critical: Any of the following

- 1. Patient in ICU
- 2. OR mechanical ventilation
- 3. OR multiorgan failure
- 4. OR shock, encephalopathy, myocardial injury or heart failure, coagulation disfunction, acute kidney injury, coma.

Abbreviations: CT= Computed tomography; ICU = Intensive Care Unit;

Reference: Parri N, Magistà AM, Marchetti F, et al. Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research Networks [published online ahead of print, 2020 Jun 3]. Eur J Pediatr. 2020;1-9. doi:10.1007/s00431-020-03683-8 (adapted)

Supplementary Table 2. Definition of tachypnea and tachycardia

Tachypnea	
Age	Respiratory rate (breaths/min)
2 months	60
2-12 months	50
1-5 years	40
>5 years	30
Tachycardia	
Age	Heart rate (beats per min)
Term	>170
3-12 months	>165
1-5 years	>150
6-11 years	>135
>11 years	>120

Supplementary Table 3. Treatments and outcomes of children SARS-CoV-2 positive

	Groups of children					
	Symptoms suggestive for COVID-19 COVID-19		Screening for hospitalisation			
	Hospitalised N=45 n (%)	Home care N=114 n (%)	Hospitalised N=3 n (%)	Home care N=24 n (%)	Hospitalised N=3 n (%)	Home care N=1 ** n (%)
Type of hospitalization*						
Pediatric ward COVID-19 ward In observation Infectious diseases ward	25 (55.6) 24 (53.3) 6 (13.3) 5 (11.1)	- - -	2 (66.7) 2 (66.7) 0 0	- - - -	1 0 1 (33.3) 0	- - -
Intensive care unit Type of respiratory	2 (4.4) 4 (2.5)	-	0	-	0	-
support any	,		-			
Oxygen High flow oxygen Non-invasive ventilation Mechanical ventilation	3 (6.7) 2 (4.4) 1 (2.2) 0	- - -	0 0 0	- - -	0 0 0	- - -
Clinical course			Ü		Ŭ	
Asymptomatic Mild Moderate Severe Critical	6 (13.3) ¹ 21 (46.7) ¹ 11 (24.4) ¹ 5 (11.1) ¹ 2 (4.4)	2 (1.8) 103 (90.4) 9 (7.9) 0	3 (100) 0 0 0 0	24 (100) 0 0 0 0	2 (66.7) 0 0 1 (33.3) 0	1 (100) 0 0 0 0
Treatment						
Antibiotic Hydroxychloroquine Steroids Anticoagulant Antiviral	16 (35.6) ¹ 4 (8.9) ¹ 4 (8.9) ¹ 2 (4.4) 2 (4.4)	12 (10.5) 0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0
Adrenaline Immunoglobulin	2 (4.4) 2 (4.4)	0	0	0	0	0
Antipyretics/analgesic Others drugs Antiepileptic	1 (2.2) ¹ 1 (2.2) 0	59 (51.8) 12 (10.5) 1 (0.9)	0 0 0	0 1 (4.2) 0	0 0 0	0 0 0
Final outcome						
Cured Referred Dead	45 (100) 0 0	114 (100) 0 0	3 (100) 0 0	24 (100) 0 0	3 (100) 0 0	1 (100) 0 0

¹ Significant difference (p<0.05) between hospitalised and home groups

* Total percentage exceeds 100% because some patients are double counted since moved from a ward to another.

** Child screened because of a day hospital

Abbreviations and symbols: IQR = inter-quartile ranges; - = not applicable.

Supplementary Table 4. Characteristics of children tested for SARS-COv-2 because of contact with a positive case or within hospitals screening

	Contact wit	h COVID-19	Screening for hospitalisation		
	Positive swab Negative swab		Positive swab	Negative swab	
	N=27	N=25	N=4	N=290	
	n (%)	n (%)	n (%)	n (%)	
Age range	0-17	0-17	0-12	0-18	
Age groups	0-17	0-17	0-12	0-10	
< 6 months	2 (7 4)	3 (12.0)	1 (25.0)	29 (0.7)	
6-24 months	2 (7.4)		1 (25.0)	28 (9.7)	
	2 (7.4)	1 (4.0)	1 (25.0)	36 (12.4)	
2-9 years	10 (37.0)	11 (44.0)	1 (25.0)	123 (42.4)	
10-18 years	13 (48.1)	10 (40.0)	1 (25.0)	99 (34.1)	
Missing	0	0	0	4 (1.4)	
Sex					
Male	11 (40.7)	11 (44.0)	1 (25.0)	186 (64.1)	
Female	16 (59.3)	14 (56.0)	3 (75.0)	100 (34.5)	
Missing	0	0	0	4 (1.4)	
Contact with COVID-19	27 (100)	25 (100)	0	3 (3.0)	
positive					
Relatives with	18 (66.7)	19 (76.0)	0	5 (1.7)	
respiratory symptoms					
Any co-morbidity	4 (14.8)	1 (4.0)	0	49 (16.9)	
Type of comorbidities	•	, ,		Ì	
Malformation, disability,	0	0	0	13 (4.5)	
neuromuscular diseases				(,	
Cardiac disease	0	0	0	5 (1.7)	
Respiratory disease	0	0	0	1 (0.3)	
Asthma	1 (3.7)	0	0	0	
Primary immunodeficiency	0	0	0	1 (0.3)	
	0				
Secondary immunodeficiency		0	0	1 (0.3)	
Obesity	2 (7.4)	0	0	0	
Diabetes	0	0	0	3 (1.0)	
Psychiatric disorder	0	0	0	9 (3.1)	
Other	1 (3.7)	1 (4.0)	0	19 (6.6)	
Disease severity at					
presentation					
Asymptomatic	27 (100)	25 (100)	3 (75.0)	135 (46.6)	
Mild	0	0	0	83 (28.6)	
Moderate	0	0	0	44 (15.2)	
Severe	0	0	1 (25.0)	25 (8.6)	
Critical	0	0	0	3 (1.0)	
Symptoms and signs at					
presentation					
Fever	0	0	0	22 (7.6)	
Respiratory symptoms,	0	0	0	14 (4.8)	
any				, ,	
Respiratory distress	0	0	0	5 (1.7)	
Rhinorrhea	0	0	0	4 (1.4)	
Dry cough	0	0	0	2 (0.7)	
Productive cough	0	0	0	0	
Sore throat	0	0	0	2 (0.7)	
Strep throat	0	0	0	0	
	0				
Conjunctivitis		0	0	2 (0.7)	
Apnea	0	0	0	0	
Thoracic pain	0	0	0	2 (0.7)	
Gastrointestinal	0	0	0	19 (6.6)	
symptoms, any		<u> </u>	_		
Vomiting	0	0	0	15 (5.2)	
Diarrhea	0	0	0	8 (2.8)	
Neurological symptoms,	0	0	1 (25.0)	18 (6.2)	
any					
Asthenia	0	0	0	2 (0.7)	
· · · · · · · · · · · · · · · · · · ·					

Headache	0	0	0	7 (2.4)
Anosmia/ageusia	0	0	0	0
Convulsion	0	0	1 (25.0)	7 (2.4)
Hyperactivity	0	0	0	2 (0.7)
Cutaneous symptoms,	0	0	0	2 (0.7)
any	l			2 (0.7)
Skin manifestations	0	0	0	2 (0.7)
Vasculitis	0	0	0	0
Unspecific flu-like	0	0	0	18 (6.2)
symptoms, any				
Muscle or joint pain	0	0	0	8 (2.8)
Nausea	0	0	0	3 (1.0)
Inappetence	0	0	0	10 (3.4)
Lymphadenitis	0	0	0	2 (0.7)
Other symptoms, any	0	0	0	61 (21.0)
Abdominal pains	0	0	0	40 (13.8)
Oral manifestations	0	0	0	0
(gingivostomatitis, aphthae)	0	0	0	1 (0.2)
Dental problems Urogenital disorders	0	0	0	1 (0.3) 10 (3.4)
Ear problems	0	0	0	1 (0.3)
Others	0	0	0	11 (3.8)
Vital parameters at				11 (5.0)
presentation				
Tachycardia	0/5	0/5	0/1	15/142 (10.6)
Tachypnea	0/4	0/3	0/1	2/56 (3.6)
Oxygen saturation level				
at presentation	<u> </u>			
91-92	0/5	0/7	0/1	0/121
≤90	0/5	0/7	0/1	0/121
Clinical examination at				
presentation Lungs auscultations				
Negative	7/9 (77.8)	13/13 (100)	1/1 (100)	211/216 (97.7)
Crackles	0/9	0/13	0/1	2/216 (0.9)
Wheezing	0/9	0/13	0/1	0/216
Absent breath sounds	0/9	0/13	0/1	1/216 (0.5)
Laboratory test ¹		0/13	0/ 1	1/210 (0.5)
White blood cell count <5.5	0/2	0/1	0/1	2/62 (96.8)
(×109/L)	<i>.</i> 		,	
Lymphocyte count <1.2 (×109/L)	0/1	0/1	0	3/36 (8.3)
Neutrophil <1.50 (×109/L)	0/2	0/1	0/1	3/57 (94.7)
C-reactive protein > 1 gr/dl	0/2	0/1	0/1	22/52 (42.3)
Erythrocyte sedimentation rate > 20 mm/h	0	0	0	3/5 (60.0)
Aspartate aminotransferase > 50 (U/L)	0/1	0/1	0	3/23 (13.0)
Alanine aminotransferase > 45 (U/L)	2/2 (100)	0/1	0/1	4/49 (8.2)
D dimer >0.5 (μg/mL)	0	0	0	1/1 (100)
Chest X-ray	0	1 (4.0)	0	8 (2.8)
Ground glass opacities ¹	0	0	0	3/8 (37.5)
Negative ¹	0	1 (4.0)	0	4/8 (50.0)
Focal consolidation ¹	0	0	0	1/8 (12.5)
Other description ¹	0	0	0	0/8
Lung ultrasound	1 (3.7) 0	0	0	0
Ground glass opacities ¹ Negative ¹	1 (3.7)	0	0	0
Focal consolidation ¹	0	0	0	0
Other description ¹	0	0	0	0
CT scan	0	0	1 (25.0)	0
Ground glass opacities ¹	0	0	1/1 (100)	0

Hospitalised ²	3 (11.1)	0	3 (75.0)	272 (93.8)
Respiratory support ¹	0	0	0	2 (0.7)
Oxygen	0/3	0/0	0/3	0/272
High flow oxygen	0/3	0/0	0/3	0/272
Noninvasive ventilation	0/3	0/0	0/3	1/272 (0.4)
Mechanical ventilation	0/3	0/0	0/3	2/272 (0.7)
Cases in ICU	0/3	0/0	0/3	2/272 (0.7)
Outcome				
Cured	27 (100)	25 (100)	4 (100)	289 (99.7)
Referred	0	0	0	1(0.3)
Dead	0	0	0	0

No significant difference (p<0.05) between positive and negative swab in each group.

¹ Note: available in a subsample of cases


² Note: one child with social problem, one child with burns, one newborn

Supplementary Table 5. Disease severity by sex and age in children COVID-19 positive and symptoms suggestive of COVID-19

Disease severity	Sex					
	N=	Male N=77 n (%)		Female N=82 n (%)		
Asymptomatic Mild Moderate Severe Critical	4 (56 (13 (3 (4 (5.2) 56 (72.7) 13 (16.9) 3 (3.9) 1 (1.3)		4 (4.9) 68 (82.9) 7 (8.5) 2 (2.4) 1 (1.2)		
		Age				
	< 6 months N=19 n (%)	6-24 months N=17 n (%)	2-9 years N=37 n (%)	10-18 years N=86 n (%)		
Asymptomatic Mild Moderate	3 (15.8) 11 (57.9) 3 (15.8)	1 (5.9) 14 (82.4) 1 (5.9)	2 (5.4) 32 (86.5) 1 (2.7)	2 (2.3) 67 (77.9) 15 (17.4)		
Severe Critical	1 (5.3) 1 (5.3)			2 (2.3) 0		

None significant difference (p<0.05) by age and sex

Supplementary Figure 1. Geographical distribution of total cases (N=2494) and positive cases (N=190)



Supplementary Figure 2. Percentage of SARS-CoV-2 positive cases across centers

